ReviewTrends in immunology2026
Human antibodies as emerging drugs for antimicrobial resistance.
Review in Trends in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial resistance (AMR) is one of today's most worrisome health emergencies. Bacteria, once easily treatable with antibiotics, have acquired resistance to many or all available drugs. In 2019, 1.27 million infection-related deaths were directly caused by AMR. By 2050, AMR could put 10 million lives per year at risk, particularly in low- and middle-income countries. This review focuses on monoclonal antibodies (mAbs) as a novel class of antimicrobials that can bypass classical resistance mechanisms and exert prophylactic and therapeutic effects. The advantages and limitations of mAbs are discussed, along with the need for rapid diagnostics for personalized use. The risk of selecting resistant strains is also addressed, as well as strategies to reduce production costs, expand global access, and improve equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.